Dr. Yashodhar P. Bhandary

Professor

  • PhD, MGIMS, Sevagram, Nagpur University
  • yash28bhandary@gmail.com

 

Dr. Bhandary obtained his M.Sc in Medical Biochemistry from Kasturba Medical College, Mangalore and Ph.D in Medical Biochemistry from Mahatma Gandhi Institute of Medical Sciences, Sevagram, Nagpur University, where he worked on the seroreactivity and polymorphism study of filarial parasites. Following his Ph.D, Dr. Bhandary did his post-doctoral studies at the University of Texas Health Science Centre, Tyler, Texas, USA, on the posttranscriptional regulation of p53-fibrinolytic system in lung diseases.

Dr. Bhandary is currently an Associate Professor at Yenepoya Research Centre, Yenepoya (Deemed to be University) where his research focuses on the role of inflammatory cytokines in regulating p53-fibrinolytic system in lung diseases.

PostDoc/Experience

  • Associate Professor (Oct 2017–till date) – Yenepoya Research Centre, Yenepoya University, Mangaluru, Karnataka, India
  • Assistant professor (Apr 2015-Sept 2017) – Yenepoya Research Centre, Yenepoya University, Mangaluru, Karnataka, India
  • Senior Research Associate (2011-2015) – Department of Cellular and Molecular Biology, The University of Texas Health Science Center at Tyler, Texas, U.S.A.
  • Postdoctoral Research Associate (2008-2011) – Department of Cellular and Molecular Biology, The University of Texas Health Science Center at Tyler, Texas, U.S.A.
  • Postdoctoral researcher (2005-2008) – Department of Cellular and Molecular Biology, The University of Texas Health Science Center at Tyler, Texas, U.S.A.
  • Lecturer (2004-2005) – K. S. Hegde Medical Academy, Nitte University, Mangaluru, Karnataka, India

Awards/Honors

  • Senior Research Fellowship (2000-2004) awarded by Department of Biotechnology, New Delhi, India
  • Junior Research Fellowship (1997-2000) awarded by Department of Biotechnology, New Delhi, India
  • Young Scientist Award in the ACBICON 2003 held in Bangalore, India.

 

 

Research

  1. Lung Injury and Fibrosis
    Research area: Inflammatory cytokine and apoptosis
    IL-17A mediated p53-fibrinolytic system is the key phenomenon during the progression of lung injury, which in turn results in the alveolar epithelial cell apoptosis. Our aim is to solve the complications of BLM induced pathogenesis pathway and regulation of this action using curcumin intervention.
    Research area: Epithelial to mesenchymal transition (EMT)
    Epithelial to mesenchymal transition is said to be involved in the pathogenesis of idiopathic pulmonary fibrosis. Our study involves investigation on inflammatory and fibrinolytic system mediated molecular mechanism during EMT. The study may provide the novel molecular target to regulate the EMT during the progression of fibrosis.
  2. Chronic Obstructive Pulmonary Diseases
    Research area: Inflammatory cytokine in smokers with or without COPD
    Cigarette smoke plays a key role in the progression chronic obstructive pulmonary disease (COPD). Our study involves the clinical significance of IL-17A mediated p53-fibrinolytic pathway and AECs apoptosis in COPD patients. The study provides insight into molecular target to regulate COPD.
    Research area: Yoga in COPD
    COPD is a respiratory disease mainly caused by cigarette smoke, environmental or occupational conditions. Keeping good respiratory health is the easiest way to regulate this disease. Yogic science provides great knowledge about ventilation related health. Yogic exercises are the best way to control the respiratory mechanism by our own.
  3. Other Inflammatory Related Diseases
    Research area: Inflammatory cytokines and microRNAs profiles in psoriasis
    Psoriasis is a chronic inflammatory skin disease characterized by inflammation, itchy and scaly skin. Studying microRNAs expression profile may provide great knowledge about the inflammatory and pathogenic mechanism taking place during psoriasis.
    Research area: Dissecting inflammatory cytokine mediated mechanism in Sepsis
    In this study we will determine how inflammatory cytokine mediated fibrinolytic system will regulate the outcome of ALI. This will addresses a critical gap in knowledge about the pathogenesis of ALI and will broaden the interventional repertoire for sepsis-induced ALI.

Publications                                                                                                                                           Full List :

  1. Marudamuthu AS*, Bhandary YP*, Fan L*, Radhakrishnan V, MacKenzie B, Maier E, … Shetty S. Caveolin-1–derived peptide limits development of pulmonary fibrosis. Science Transnational Medicine. 11(522), eaat2848. (*-equal first author)
  2. Bhandary YP, Idell S, and Shetty S ( Correspondance). Regulation of Urokinase Receptor Expression: Interpreting Data in the Absence of Statistics. Am J. Respir. Crit. Care Med. 180, 583; 2009.
  3. Shetty S, Bhandary YP, Shetty P, Idell S, Velusamy T, Bdeir K, Cines DB, Ruppert C, Gunther A, Neuschaunder PF, Gyetko, MR and Shetty, RS. Induction of Tissue Factor by Urokinase in Lung Epithelial Cells. Am J Resp. Crit Care Med. 181, 1355-1366;2010.
  4. Bhandary YP, Shetty SK, Marudamuthu AS, Gyetko MR, Idell S, Kermani MG, Shetty RS, Starcher BC, Shetty S. Regulation of alveolar epithelial cell apoptosis and pulmonary fibrosis by coordinate expression of components of the fibrinolytic system. Am J Physiology: Lung cellular Mol Physiol. 302, L463-L473; 2012.
  5. Bhandary YP, Shetty SK, Marudamuthu AS, Ji HL, Neuenschwander PF, Boggaram V, Morris GF, Fu J, Idell S and Shetty S. Regulation of alveolar epithelial injury and lung fibrosis by p53-mediated changes in urokinase and plasminogen activator inhibitor-1. J. Path. 183(1): 131-43; 2013.

 

 

 

  1. Yashodhar P. Bhandary, Sadiya Bi Shaikh, Dr. Irfan, “Biomarkers for Detection/ Diagnosis of Pulmonary Disorders and Uses Thereof”, Indian Patent, Provisional specification, 2019, 201941051398.
  2. Yashodhar P. Bhandary, Sadiya Bi Shaikh, Mr. Mohd. Altaf Najar, Dr. Ashwini Prabhu, Dr. Prashant Kumar Modi and Dr. T. S. Keshava Prasad,“Molecular Biomarkers for Detection of Idiopathic Pulmonary Fibrosis”, Indian Patent, Provisional specification, 2019, 201941048222.

 

 

 

PI

  1. BRNS Grant: Studies on the role of Curcumin in blocking p53 in the reduction of severity of g-irradiation induced apoptosis of alveolar epithelial cells. (Cost: 25 Lakhs)
  2. DBT Grant: Fibrinolytic system and miR 200a in EMT and pulmonary fibrosis. (Cost: 34 Lakhs)

Co-PI

  1. ICMR Grant: A Study On The Role Of Steridiogenesis Activating Transcription Factor 3 In The Development Of Hypospadias On Male Mice Induced By FinasterideA Randomized Controlled Trial. (Cost: 30 Lakhs)
  2. DST-SATYAM: Long term effect of yoga on psycho-neuro endocrine functions among adolescent healthy volunteers. (Cost: 40 Lakhs)
  3. ICMR: Gut microbiome and cancer cells crosstalk as a molecular drug target for colon cancer. (Cost: 30 Lakhs)
  4. DST: Deciphering the role of vitamin D on lncRNA-pERK1/2-AKT-FOXO axis during skeletal muscle differentiation: Implications to skeletal muscle atrophy and osteoarthritis”. (Cost: 41 Lakhs)
  5. DBT: Therapeutic potential of AHL analogues through neutrophil extracellular traps mediated bacterial clearance during chronic obstructive pulmonary disease. (Cost: 44 Lakhs)

Completed

  1. ICMR: Therapeutic potential of curcumin in regulation of IL-17A during acute lung injury and fibrosis. (Cost: 8 Lakhs)
  2. DBT-SERB Grant: A novel strategy for enhancing the efficacy of platelet rich plasma (PRP) in diabetic wound care. (Cost: 43 Lakhs)
  3. DBT Grant: Development of a wound healing material from the biopolymers produced by two novel bacterial strains isolated from west coast of India. (39.2 Lakhs)